Sanofi-aventis and JDRF Form Partnership
to Improve Therapies, Work Toward Cure
for Type 1 Diabetes
Paris, France – July 1, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and the Juvenile Diabetes
Research Foundation (JDRF) announced today a unique partnership to develop therapeutic treatments for people with
type 1 diabetes at different stages of the disease – both those living with the disease and the newly diagnosed – as
well as preventing diabetes in those at risk. Toward those goals, the partnership will focus on therapeutics such as
immune therapies and beta cell regeneration.
Under the newly announced partnership, sanofi-aventis and JDRF will jointly provide academic investigators and non-
profit medical research organizations with funding to conduct research projects in regeneration and immune therapy.
This partnership will provide sanofi-aventis with options to the intellectual property developed by researchers who
receive funding through the program.
“Sanofi-aventis is committed to providing healthcare solutions that meet the needs of people with diabetes and their
families,” said Pierre Chancel, Senior Vice-President, Global Diabetes, sanofi-aventis. “Our long-acting insulin is one
of the leading insulin products for patients with type 1 and type 2 diabetes, and we continue to invest in research for
additional therapies and solutions to meet the unmet needs of patients. Our partnership with the Juvenile Diabetes
Research Foundation is an opportunity to help fund innovative research that will improve therapies and perhaps even
find a cure for type 1 diabetes.”
The partnership will capitalize on the JDRF’s network of academicians, institutions and biotech partners, while also
leveraging sanofi-aventis’ drug development experience to help bring products and technologies to the clinic and
eventually to patients.
“JDRF is focused on immune therapies and regeneration as two key areas to develop better treatments and cures for
diabetes,” said Jeffrey Brewe